Enveric Biosciences (ENVB) is a pre-revenue clinical-stage pharmaceutical company with zero product revenue and an accumulated deficit of $114.8M as of December 31, 2025. Under a liquidation lens, recovery to equity is thin and structurally precarious. Total assets per XBRL are $5.10M, of which $4.68M is cash (100% recoverable), $0.26M is prepaid and other current assets (near-zero recovery under liquidation; primarily insurance prepayments and deferred offering costs), and $0.16M is net PP&E consisting entirely of lab equipment and leasehold improvements in Calgary, Canada (haircut to 50-60% suggests ~$80-95K recovery). There are no inventory, AR, or goodwill line items. Intangibles were fully amortized in Q1 2025 per the prior filing MD&A; no intangible balance remains on the balance sheet, consistent with zero recovery assumption. Total current liabilities are $918K, comprising $581K accounts payable, $238K accrued liabilities, and $100K due to related parties (board compensation). No long-term debt, no pension, no ASC 842 operating lease ROU asset or corresponding lease liability is separately tagged in XBRL, though the company maintains Calgary lab space. Filing does not separately tag an operating lease liability in XBRL, though the lab equipment and leasehold improvements imply an active facility. Consulting and vendor commitments of approximately $0.4M are disclosed in Note 9 but not separately XBRL-tagged; these represent contingent wind-up obligations. Net liquidation value approximates: cash $4.68M + haircut prepaids ~$0 + haircut PP&E ~$90K less total liabilities at face $918K yields roughly $3.85M gross recovery against stockholders' equity of $4.18M — broadly consistent with MFFAIS's CLV/LLV/OLV of $8.44M, though the MFFAIS figure appears to use book equity rather than a haircut asset approach. The company raised $10.6M in financing cash flows in 2025 (public offering, two inducement warrant transactions, ATM) but burned $8.1M in operating cash, resulting in a net cash increase of $2.4M YoY from $2.24M at year-end 2024 to $4.68M at year-end 2025. Going concern language from the prior 10-Q (Q3 2025) is not explicitly reproduced in this 10-K filing body; however, the ongoing cash burn rate of ~$8M/year against ending cash of $4.7M and vendor commitments of $0.4M signals a runway of approximately six to eight months absent further financing. The 10-K does not separately tag a going concern disclosure in XBRL, but the economics are self-evident. A subsequent event on January 27, 2026 (registered direct offering for $1.5M gross) and ATM issuance of $1.3M in February 2026 provide modest liquidity extension. The December 2025 inducement warrant transaction generated a $1.85M deemed dividend that increases reported net loss attributable to common stockholders to $12.1M despite a $8.77M GAAP net loss, a distinction material only to EPS calculation and not to the liquidation stack.
▼ Community Notes